[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612990":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":58,"locations":7,"responsibleParty":64,"collaborators":7,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":7,"enrollmentInfo":76,"targetDuration":79,"studyType":80,"phases":7,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":88,"whyStopped":7,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":7},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",null,[9,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55],{"name":10,"affiliation":11,"role":12},"Xiaofang Niu","Heze Municipal Hospital","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":15,"role":12},"Leqing Zhang","Yanggu County People's Hospital",{"name":17,"affiliation":18,"role":12},"Lei Duan","Zibo Central Hospital",{"name":20,"affiliation":21,"role":12},"Kai Ren","Haiyang People's Hospital",{"name":23,"affiliation":24,"role":12},"Rongrong Zhang","Sishui County People's Hospital",{"name":26,"affiliation":27,"role":12},"Ping Yang","Jinan Fourth People's Hospital",{"name":29,"affiliation":30,"role":12},"Ning Liu","Shandong Hospital of Integrated Traditional Chinese and Western Medicine",{"name":32,"affiliation":33,"role":12},"Pengcheng Du","Qilu Hospital of Shandong University, Dezhou Branch",{"name":35,"affiliation":36,"role":12},"Hui Liu","Jinan Municipal People's Hospital",{"name":38,"affiliation":39,"role":12},"Xi Rong","Weifang Yidu Central Hospital",{"name":41,"affiliation":42,"role":12},"Deyin Zhai","Linyi Traditional Chinese Medicine Hospital",{"name":44,"affiliation":45,"role":12},"Zhiqiang Zhang","Anqiu People's Hospital",{"name":47,"affiliation":48,"role":12},"Jiyong Wu","Shandong Provincial Second People's Hospital",{"name":50,"affiliation":51,"role":12},"Meixia Wang","Jining Medical University Affiliated Hospital",{"name":53,"affiliation":54,"role":12},"Ping Wang","Liaocheng People's Hospital",{"name":56,"affiliation":57,"role":12},"Jiyao Li","Liaocheng Municipal People's Hospital",[59],{"name":60,"role":61,"phone":62,"phoneExt":7,"email":63},"Yan Li","CONTACT","13791126823","li_xyan@126.com",{"type":12,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"LI YAN","Chief Pharmacist","100612990","clinical-comprehensive-evaluation-of-neuroprotective-drugs-for-acute-ischemic-stroke-100612990",false,"NCT07260760","Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke","Ischemic strok","Inclusion Criteria:\n\n* 1: Age≥18\n\n  2: Acute ischemic stroke in the anterior circulation occurring within 48 hours\n\n  3: Baseline NIHSS score of 1-15 points (mild stroke: baseline NIHSS score of 1-5 points; moderate stroke: baseline NIHSS score of 6-15 points)\n\n  4: Pre-onset mRS score≤1\n\n  5: Use of Edaravone (injection or tablets)\n\n  6: Exclude intracranial hemorrhage\n\n  7: Sign the informed consent form\n\nExclusion Criteria:\n\n* 1: A head CT or MRI scan indicates the presence of intracranial hemorrhagic disease\n\n  2: Patients with cerebral embolism or suspected cerebral embolism who also have severe atrioventricular block, atrial fibrillation, myocardial infarction, valvular heart disease, infective endocarditis, or a heart rate below 50 beats per minute\n\n  3: Abnormal liver function (ALT or AST transaminase levels exceeding the upper limit of normal), abnormal kidney function (creatinine levels exceeding the upper limit of normal), or individuals with other severe systemic diseases, etc\n\n  4: Allergy to the test drug","ALL","18 Years",{"count":77,"type":78},600,"ESTIMATED","90 Days","OBSERVATIONAL","This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.",[83],"Acute Ischemic Stroke",[85,86,87],"Acute ischemic stroke","Neuroprotective drugs","Real-world studies","NOT_YET_RECRUITING","2026-01-14",{"date":91,"type":92},"2026-01-15","ACTUAL",{"date":94,"type":78},"2026-01-20",{"date":96,"type":78},"2028-12-31",{"name":5,"class":6}]